Clinical trials
Immune Thrombocytopenia (ITP) clinical trials
Below are recruiting immune thrombocytopenia (itp) clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06853444RecruitingPhase 1/Phase 2
ESG206 for adults with hard-to-treat ITP
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07065968RecruitingPhase 2
Teriflunomide and steroids for new immune thrombocytopenia
This trial tests if adding teriflunomide to high-dose dexamethasone helps adults newly diagnosed with immune thrombocytopenia (ITP) who have low platelets or bleeding. It aims to find a safer, more effective way to raise platelet counts.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07059000RecruitingPhase 3
Study of a drug for adults with chronic ITP
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
Los Angeles, CaliforniaAges 18–70 - NCT07063199RecruitingPhase 2
Anti-CD38 antibody for older adults with hard-to-treat ITP
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07043946RecruitingPhase 1/Phase 2
Budoprutug for immune thrombocytopenia
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
PlovdivAges 18 years+ - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT06973356Recruiting
CAR-T therapy for severe, hard-to-treat ITP
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
Changsha, HunanAges 18 years+ - NCT06962631RecruitingPhase 3
V-IMMUNE for Immune Thrombocytopenia (ITP) Study
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
Recife, PernambucoAges 1 year+ - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT06929299RecruitingPhase 1/Phase 2
Testing STSA-1301 for immune thrombocytopenia (ITP)
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Bengbu, AnhuiAges 18–75 - NCT06880081RecruitingPhase 1
A study of PN20 for adults with immune thrombocytopenia
This trial tests a new drug called PN20 for adults with a long-term low platelet condition called immune thrombocytopenia (ITP). It aims to see if the drug can safely raise platelet counts for people who have not gotten better with other treatments.
Guiyang, GuizhouAges 18–65 - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT06817395Recruiting
Thinking and memory in chronic ITP
This study looks at whether chronic or persistent immune thrombocytopenia (ITP) affects thinking and memory. If you have had low platelet counts for 3 months or more and have been treated for ITP, you may help researchers understand how the condition can impact the brain.
Boston, MassachusettsAges 18 years+ - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06721013RecruitingPhase 1/Phase 2
Study of Pirtobrutinib for immune thrombocytopenia
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06722235RecruitingPhase 3
Mezagitamab for chronic immune thrombocytopenia
This study tests a new medicine called mezagitamab for people with chronic ITP (low platelets for over a year). The medicine may help raise your platelet count and reduce bleeding risk.
Hot Springs, ArkansasAges 18 years+ - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06519565RecruitingEarly Phase 1
Testing PRG-1801 for hard-to-treat immune thrombocytopenia
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Wuhan, HubeiAges 18 years+ - NCT06168851RecruitingPhase 2
Anti-CD38 antibody for children with chronic ITP
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 6–17 - NCT06107582Recruiting
Long-term study of children with immune thrombocytopenia
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
TianjinAges 6–17 - NCT04800458Recruiting
Testing antibody findings to confirm autoimmune low platelets
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
PessacAges 18 years+ - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT06531018RecruitingPhase 1/Phase 2
Eltrombopag for newly diagnosed ITP patients
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
DhakaAges 18–70
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune thrombocytopenia (itp)?
- Yes. Clin2 currently lists 80 recruiting immune thrombocytopenia (itp) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune thrombocytopenia (itp) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune thrombocytopenia (itp) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.